Home
L_Carnitine Plus – 1000 mg Levocarnitine tablets

L_Carnitine Plus – 1000 mg Levocarnitine tablets

L_Carnitine Plus indicated for the treatment of primary and secondary carnitine deficiency in adults and children over 12 years of age.

Compostion

Each film coated tablet contains:

  • L-carnitine L-tartarate 1000 mg.
  • Zinc gluconate 50mg.

Pharmaceutical form: Film coated tablets

Dosage and method of administration

  • Adults and children over 12 years of age: The tablets should be given in divided doses. It is advisable to monitor therapy by measuring carnitine levels in both plasma and urine.
  • The management of inborn errors of metabolism: The dosage required depends upon the specific inborn error of metabolism concerned and the severity of presentation at the time of treatment. However, the following can be considered as a general guide:
  • An oral dosage of up to 200mg/kg/day in divided doses (2 to 4) is recommended for chronic use in some disorders, with lower doses sufficing in other conditions. if clinical and biochemical symptoms do not improve, the dose may be increased on a short-term basis.
  • Higher doses of up to 400mg/kg/day may be necessary in acute metabolic decompensation or the i.v. route may be required.
  • Haemodialysis – maintenance therapy: If significant clinical benefit has been gained by a first course of intravenous carnitine then maintenance therapy can be considered using 1 g per day of L_Carnitine Plus orally. On the day of the dialysis oral L_Carnitine Plus has to be administered at the end of the session.

Special warnings and precautions for use

  • While improving glucose utilization, the administration of L-carnitine to diabetic patients receiving either insulin or hypoglycaemic oral treatment may result in hypoglycaemia. Plasma glucose levels must be monitored regularly in order to adjust the hypoglycaemic treatment immediately, if required.
  • The safety and efficacy of oral L-carnitine has not been evaluated in patients with renal insufficiency. Chronic administration of high doses of oral L-carnitine in patients with severely compromised renal function or in end stage renal disease (ESRD) patients on dialysis may result in an accumulation of the potentially toxic metabolites, trimethylamine (TMA) and trimethylamine-N-oxide (TMAO), since these metabolites are usually excreted in the urine. This situation has not been observed following intravenous administration of L-carnitine.
  • Ask a doctor before use if you are taking minocycline, doxycycline, tetracycline or are on coumadin therapy, zinc. L_Carnitine Plus may inhibit the absorption of these medicines.

Undesirable Effects

  • Various mild gastro-intestinal complaints have been reported during the long term administration of oral levocarnitine, these include transient nausea and vomiting, abdominal cramps and diarrhoea.
  • Decreasing the dosage often diminishes or eliminates drug related patient body odour or gastro-intestinal symptoms when present.
  • Tolerance should be monitored very closely during the first week of administration and after any dosage increase.

L_Carnitine Plus – Product Information

Our goal is to provide you with the most relevant and up-to-date information. However, because pharmaceutical products affect each person differently, we cannot guarantee that this article includes all the information you should know, and you should always consult your doctor, pharmacist or health provider. Copyright: “All rights reserved (c) pharmacia1 .com” – Contact us via the contact form, or simply write a comment at the bottom of the page.